Block Listing Six Monthly Return

RNS Number : 0314K

Alliance Pharma PLC

29 December 2020

 

For immediate release

29 December 2020

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Block Listing Six Monthly Return

Name of applicant:		ALLIANCE PHARMA PLC
Names of schemes:		a)  The Alliance Pharma plc Approved Share Option Plan 2005 b)  The Alliance Pharma plc Share Option Plan 2006 c)  The Alliance Pharma plc Company Share Option Plan 2015
Period of return:	From:	28 June 2020	To:	28 December 2020
Number of securities originally admitted at date of admission:		25,000,000 ordinary shares of 1p each 28 June 2017
Balance of unallotted securities under schemes from previous return:		a)  356,536 b)  5,362,778 c)  14,923,223
Plus:   The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for):		a)  Nil b)  Nil c)  Nil
Less:   Number of securities issued/allotted under schemes during period:		a)  63,164 b) 96,156 c)  1,701,727
Equals:   Balance under schemes not yet issued/allotted at end of period:		a)  293,372 b)  5,266,622 c)  13,221,496

Name of contact:	Chris Chrysanthou, Company Secretary
Telephone number of contact:	Tel. [phone]

For further information:

Alliance Pharma plc      + 44 (0) 1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk  

Buchanan         + 44 (0) 20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited         + 44 (0) 20 7260 1000

Nominated Adviser: Freddie Barnfield / Huw Jeremy

Corporate Broking: James Black

Investec Bank plc     [phone]

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Tejas Padalkar

About Alliance Pharma

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.

We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website:  www.alliancepharmaceuticals.com  

 

END

 

 

BLRKKCBQBBDDKBB